EMA limits use of JAK inhibitors for at-risk groups in wake of safety concerns
Following the US’ lead, the EMA is cutting back on the use of JAK inhibitors for some patients over a suite of safety concerns. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
